ArticleIn vivo (Athens, Greece)

Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.

Stamatis J Karakatsanis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.